Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity (Met-IER)

13 september 2019 uppdaterad av: King's College London

A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity

An intermittent energy restricted (IER) diet may modify cardio-metabolic disease risk factors compared to an energy-matched continuous energy restricted (CER) diet. A randomised controlled parallel design trial will determine the impact of a short-term IER diet (2 consecutive days of very low calorie diet (VLCD), 5 days moderate energy restriction each week for a 4 week period), compared to a CER diet, on insulin sensitivity in healthy (disease-free) subjects with central obesity.

Studieöversikt

Detaljerad beskrivning

Prediabetes rates in England have showed a marked increase, more than tripling between 2003 and 2011. It is characterised by an impaired fasting glucose or impaired glucose tolerance that increases the risk of progression to type 2 diabetes (T2D). It has been estimated that approximately 90% of T2D is attributed to excess weight. Central obesity is a primary driver of increased cardiometabolic risk due to its lipotoxicity effects, promoting a proinflammatory state that facilitates insulin resistance and beta cell dysfunction. A high waist circumference measurement, indicative of central obesity, is associated with increased risk of cardiovascular diseases and T2D, and is a stronger predictor of T2D than BMI. BMI has limitations as an indicator of adiposity since it doesn't distinguish lean from fat mass, and does not indicate body fat distribution. Conventionally, continuous energy restriction (CER) diets have been used for weight loss, which consist of a constant daily energy deficit relative to total energy expenditure. The impact on weight loss and health of an intermittent energy restriction (IER) approach has only rarely been investigated (although the "5:2 diet" has been popularised in lifestyle books aimed at the general public). An IER diet consists of a predefined period of time severely restricting energy intake, alternated with a period of greater energy intake. This approach was shown to confer metabolic benefits in overweight and obese women at risk of breast cancer with baseline BMI of 2445 (Harvie et al., 2013; Harvie et al., 2011).

Rationale: An IER diet using meal replacements (VLCD foodpacks used as total dietary replacements for 2 consecutive days each week, and a food-based energy-restricted diet for the other 5 days of the week) may modify cardio-metabolic disease risk factors compared to an energy-matched CER diet.

Research question: In centrally obese subjects, assessed by a high waist circumference measurement, does adherence to an IER diet have enhanced cardio-metabolic benefits compared to a CER diet? Hypothesis: Increases in insulin sensitivity following a 4 week dietary intervention with an IER weight loss programme will be greater compared to a standard CER programme.

Objectives:

  1. A randomised controlled parallel design trial will determine the impact of a short-term IER diet compared to a CER diet on primary outcome variables (insulin sensitivity) in healthy subjects with a high waist circumference.
  2. To assess the impact of an IER diet on secondary outcome variables, including body composition, heart rate variability (HRV, a measure of cardiac autonomic function, including parasympathetic and sympathetic activity), blood pressure, vascular function, other markers of insulin resistance, inflammation/adipokines, plasma lipid profile, plasma norepinephrine, ketosis, the gut microbiome and cognitive function in healthy subjects with a high waist circumference.

Studietyp

Interventionell

Inskrivning (Faktisk)

42

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • England
      • London, England, Storbritannien, SE1 9NH
        • Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Buiding, 150 Stamford St.

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

35 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Aged >35-75 years
  • Waist circumference above cut-off for high risk of cardio-metabolic disease of >102 cm in men with a Europid, Black African and Caribbean, and other ethnic background and >88 cm in women with a Europid, Black African and Caribbean, and other ethnic background (WHO, 2008), and ≥90 cm in men and ≥80 cm in women with an Asian background (South Asian and East Asian) (Misra et al., 2009).

REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India 57: 163170.

WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008.

Exclusion Criteria:

  • Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver disease;
  • previous bariatric surgery or other major surgery (e.g. organ transplantation);
  • unable to provide written informed consent;
  • have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder, attention deficit disorder, post-traumatic stress disorder, obsessive compulsive disorder) or uncontrolled depression;
  • participated in a weight management drug trial in the previous 3 months;
  • have binge eating behaviour;
  • have uncontrolled epilepsy;
  • alcohol or substance abuse;
  • currently pregnant, lactating, or planning pregnancy within the study period;
  • are using medication clinically deemed to affect metabolic rate and weight (e.g. beta blockers, corticosteroids, diuretics, etc);
  • lactose intolerant.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Intermittent Energy Restriction
Weight loss intervention: Intermittent Energy Restriction
Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
Aktiv komparator: Continuous Energy Restriction
Weight loss intervention: Continuous Energy Restriction
Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Revised QUICKI (RQUICKI)
Tidsram: Baseline
Marker of insulin sensitivity
Baseline
RQUICKI
Tidsram: day 29
Marker of insulin sensitivity
day 29
RQUICKI
Tidsram: day 31
Marker of insulin sensitivity
day 31

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Kroppsvikt
Tidsram: Baslinje
Baslinje
Midjemått
Tidsram: Baslinje
Baslinje
Höftomkretsen
Tidsram: Baslinje
Baslinje
Koncentration av glukos i plasma
Tidsram: Baslinje
Fasta
Baslinje
Koncentration av adiponektin i plasma
Tidsram: Baslinje
Fasta
Baslinje
Plasma leptinkoncentration
Tidsram: Baslinje
Fasta
Baslinje
Total kolesterolkoncentration i plasma
Tidsram: Baslinje
Fasta
Baslinje
Plasma lågdensitet lipoprotein (LDL) kolesterolkoncentration
Tidsram: Baslinje
Fasta
Baslinje
Plasma högdensitetslipoprotein (HDL) kolesterolkoncentration
Tidsram: Baslinje
Fasta
Baslinje
Plasmatriglyceridkoncentration
Tidsram: Baslinje
Fasta
Baslinje
Totalt kolesterol i plasma: HDL-kolesterolförhållande
Tidsram: Baslinje
Fasta
Baslinje
Body mass index (BMI)
Tidsram: Baslinje
Baslinje
Plasma glucose concentration
Tidsram: day 29
Fasting
day 29
Plasma glucose concentration
Tidsram: day 31
Fasting
day 31
Plasma insulin concentration
Tidsram: Baseline
Fasting
Baseline
Plasma insulin concentration
Tidsram: day 29
Fasting
day 29
Plasma insulin concentration
Tidsram: day 31
Fasting
day 31
Plasma non-esterified fatty acid concentration
Tidsram: Baseline
Fasting
Baseline
Plasma non-esterified fatty acid concentration
Tidsram: day 29
Fasting
day 29
Plasma non-esterified fatty acid concentration
Tidsram: day 31
Fasting
day 31
Plasma total cholesterol concentration
Tidsram: day 29
Fasting
day 29
Plasma total cholesterol concentration
Tidsram: day 31
Fasting
day 31
Plasma LDL cholesterol concentration
Tidsram: day 29
Fasting
day 29
Plasma LDL cholesterol concentration
Tidsram: day 31
Fasting
day 31
Plasma HDL cholesterol concentration
Tidsram: day 29
Fasting
day 29
Plasma HDL cholesterol concentration
Tidsram: day 31
Fasting
day 31
Plasma triglyceride concentration
Tidsram: day 29
Fasting
day 29
Plasma triglyceride concentration
Tidsram: day 31
Fasting
day 31
Plasma total cholesterol:HDL cholesterol ratio
Tidsram: day 29
Fasting
day 29
Plasma total cholesterol:HDL cholesterol ratio
Tidsram: day 31
Fasting
day 31
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Tidsram: Baseline
Fasting (calculated from insulin and glucose)
Baseline
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Tidsram: day 29
Fasting (calculated from insulin and glucose)
day 29
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Tidsram: day 31
Fasting (calculated from insulin and glucose)
day 31
Plasma adiponectin concentration
Tidsram: day 29
Fasting
day 29
Plasma adiponectin concentration
Tidsram: day 31
Fasting
day 31
Plasma leptin concentration
Tidsram: day 29
Fasting
day 29
Plasma leptin concentration
Tidsram: day 31
Fasting
day 31
Plasma interleukin-6 concentration
Tidsram: Baseline
Fasting
Baseline
Plasma interleukin-6 concentration
Tidsram: day 29
Fasting
day 29
Plasma interleukin-6 concentration
Tidsram: day 31
Fasting
day 31
Plasma beta-hydroxybutyrate concentration
Tidsram: Baseline
Fasting
Baseline
Plasma beta-hydroxybutyrate concentration
Tidsram: day 29
Fasting
day 29
Plasma beta-hydroxybutyrate concentration
Tidsram: day 31
Fasting
day 31
Plasma norepinephrine concentration
Tidsram: Baseline
Fasting
Baseline
Plasma norepinephrine concentration
Tidsram: day 29
Fasting
day 29
Plasma norepinephrine concentration
Tidsram: day 31
Fasting
day 31
Plasma soluble alpha-klotho concentration
Tidsram: Baseline
Fasting
Baseline
Plasma soluble alpha-klotho concentration
Tidsram: day 29
Fasting
day 29
Plasma soluble alpha-klotho concentration
Tidsram: day 31
Fasting
day 31
Body weight
Tidsram: day 29
day 29
Body weight
Tidsram: day 31
day 31
BMI
Tidsram: day 29
day 29
BMI
Tidsram: day 31
day 31
Waist circumference
Tidsram: day 29
day 29
Waist circumference
Tidsram: day 31
day 31
Hip circumference
Tidsram: day 29
day 29
Hip circumference
Tidsram: day 31
day 31
Percentage body fat
Tidsram: Baseline
Baseline
Percentage body fat
Tidsram: day 29
day 29
Percentage body fat
Tidsram: day 31
day 31
Percentage lean body mass
Tidsram: Baseline
Baseline
Percentage lean body mass
Tidsram: day 29
day 29
Percentage lean body mass
Tidsram: day 31
day 31
Heart rate variability (resting)
Tidsram: Baseline
supine
Baseline
Heart rate variability (resting)
Tidsram: day 29
supine
day 29
Heart rate variability (resting)
Tidsram: day 31
supine
day 31
Heart rate variability (ambulatory)
Tidsram: 24 h recording at baseline
24 h recording at baseline
Heart rate variability (ambulatory)
Tidsram: 24 h recording on day 29
24 h recording on day 29
Heart rate variability (ambulatory)
Tidsram: 24 h recording on day 31
24 h recording on day 31
Heart rate variability (sleep-time)
Tidsram: Baseline
Baseline
Heart rate variability (sleep-time)
Tidsram: day 29
day 29
Heart rate variability (sleep-time)
Tidsram: day 31
day 31
Heart rate variability (during mental stress)
Tidsram: Baseline
Baseline
Heart rate variability (during mental stress)
Tidsram: day 29
day 29
Heart rate variability (during mental stress)
Tidsram: day 31
day 31
Ambulatory blood pressure 24 h
Tidsram: 24 h analysis at baseline
24 h analysis at baseline
Ambulatory blood pressure daytime
Tidsram: Daytime analysis at baseline
Daytime analysis at baseline
Ambulatory blood pressure night-time
Tidsram: Night-time analysis at baseline
Night-time analysis at baseline
Ambulatory blood pressure 24 h
Tidsram: 24 h analysis on day 29
24 h analysis on day 29
Ambulatory blood pressure daytime
Tidsram: daytime analysis on day 29
daytime analysis on day 29
Ambulatory blood pressure night-time
Tidsram: night-time analysis on day 29
night-time analysis on day 29
Ambulatory blood pressure 24 h
Tidsram: 24 h analysis on day 31
24 h
24 h analysis on day 31
Ambulatory blood pressure daytime
Tidsram: Daytime analysis on day 31
day time
Daytime analysis on day 31
Ambulatory blood pressure night-time
Tidsram: Night-time analysis on day 31
night-time
Night-time analysis on day 31
Digital volume pulse - stiffness index (SI)
Tidsram: Baseline
Stiffness index
Baseline
Digital volume pulse - SI
Tidsram: day 29
Stiffness index
day 29
Digital volume pulse - SI
Tidsram: day 31
Stiffness index
day 31
Digital volume pulse - reflection index (RI)
Tidsram: Baseline
reflection index
Baseline
Digital volume pulse - RI
Tidsram: day 29
reflection index
day 29
Digital volume pulse - RI
Tidsram: day 31
reflection index
day 31
Mnemonic Similarity Test
Tidsram: Baseline
Baseline
Mnemonic Similarity Test
Tidsram: day 29
day 29
Mnemonic Similarity Test
Tidsram: day 31
day 31
Power of food scale
Tidsram: Baseline
questionnaire
Baseline
Power of food scale
Tidsram: day 29
questionnaire
day 29
Power of food scale
Tidsram: day 31
questionnaire
day 31
COPE (not an acronym)
Tidsram: Baseline
questionnaire
Baseline
COPE
Tidsram: day 29
questionnaire
day 29
COPE
Tidsram: day 31
questionnaire
day 31

Andra resultatmått

Resultatmått
Tidsram
Adverse events
Tidsram: Baseline until endpoint: day 31 (+/-1 day)
Baseline until endpoint: day 31 (+/-1 day)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 februari 2016

Primärt slutförande (Faktisk)

1 juli 2016

Avslutad studie (Faktisk)

1 juli 2016

Studieregistreringsdatum

Först inskickad

22 januari 2016

Först inskickad som uppfyllde QC-kriterierna

8 februari 2016

Första postat (Uppskatta)

11 februari 2016

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 september 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 september 2019

Senast verifierad

1 juli 2016

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera